Infectious Disease Alert – May 1, 2022
May 1, 2022
View Issues
-
Midlines vs. Peripherally Inserted Central Venous Catheters
Midline catheters are, at a minimum, at least as safe or safer than peripherally inserted central catheters for durations of at least 14 days, thus offering an effective alternative for venous access.
-
Aminoglycoside-Induced Ototoxicity: Test Before You Treat?
Mitochondrially inherited, aminoglycoside-induced ototoxicity can cause irreversible hearing loss. Approximately 0.2% of the population is at risk, and new point-of-care genetic testing could prompt avoidance of aminoglycoside use without undue delay in antibiotic administration.
-
Immunosuppressants and the Risk for Clostridioides difficile Infection
A retrospective cohort study found that for patients taking immunosuppressing medications, the greatest risk for C. difficile infection occurred for those receiving calcineurin inhibitors and those taking drugs from multiple immunosuppressant classes.
-
Persistent Inflammation and Post-COVID Syndrome
Ongoing inflammation may contribute to long COVID.
-
Maribavir (Livtencity)
The FDA approved maribavir as the first drug to treat adult and pediatric patients with post-transplant cytomegalovirus infections that do not respond to currently available antiviral treatment.
-
A Case of Monkeypox in a Returned Traveler
The arrival of a traveler from Nigeria to the United States with monkeypox infection, which was quickly recognized, led to a massive public health response investigating exposed individuals, but no secondary cases were detected.
-
Infectious Disease Alert Updates
Recovering from Critical COVID; Oral and Anal Transmission of Syphilis